A Long-term, Open-label Follow-up Study Of Tofacitinib For Treatment Of Juvenile Idiopathic Arthritis (Jia)

Trial Profile

A Long-term, Open-label Follow-up Study Of Tofacitinib For Treatment Of Juvenile Idiopathic Arthritis (Jia)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Adverse reactions; Registrational
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 10 Jun 2013 Planned end date changed from 1 Aug 2019 to 1 Sep 2020 as reported by ClinicalTrials.gov.
    • 12 Dec 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top